

CHEMIPHAR TO ACQUIRE MARKETING AUTHORIZATION FOR ORAL INTESTINAL CLEANSING AGENT PICOPREP® IN JAPAN

Nippon Chemiphar Co., Ltd.
(TSE: 4539)
February 8, 2019

Nippon Chemiphar Co., Ltd. (HQ: Tokyo; President & CEO: Kazushiro Yamaguchi; hereinafter “Chemiphar”), announces today that Chemiphar will acquire the marketing authorization for oral intestinal cleansing agent PICOPREP® combination powder from Ferring Pharmaceuticals Co., Ltd. (HQ: Tokyo; CEO: Mark Noggle), commencing on February 12, 2019, based on a contract between both companies.

Applicable item

Product name	PICOPREP® combination powder
Indication for use	Cleans bowels prior to endoscopy, also cleans bowels prior to surgery when deemed clinically necessary.

Chemiphar focuses on the oncology and digestive fields for generics, selling various kinds of digestive organ drugs, and established an oncology promotion section in 2013, dispatching specialists to all branch offices enabling MRs to provide cancer-related information. We will focus on PICOPREP® sales promotion and information provision.

For further information contact:

Public Relations Department, Nippon Chemiphar Co., Ltd.

E-mail: ir@chemiphar.co.jp